861 related articles for article (PubMed ID: 1182674)
1. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
Durie BG; Salmon SE
Cancer; 1975 Sep; 36(3):842-54. PubMed ID: 1182674
[TBL] [Abstract][Full Text] [Related]
2. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
Merlini G; Waldenström JG; Jayakar SD
Blood; 1980 Jun; 55(6):1011-9. PubMed ID: 7378577
[TBL] [Abstract][Full Text] [Related]
3. Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems.
Cooper DA; Miller AC; Penny R
Acta Haematol; 1982; 68(3):224-36. PubMed ID: 6814151
[TBL] [Abstract][Full Text] [Related]
4. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
Bataille R; Durie BG; Grenier J
Br J Haematol; 1983 Nov; 55(3):439-47. PubMed ID: 6357266
[TBL] [Abstract][Full Text] [Related]
5. Prognostic variables and clinical staging in multiple myeloma.
Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
[TBL] [Abstract][Full Text] [Related]
6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
7. [Clinical and quantitative staging and monitoring of multiple myeloma. Analysis of 145 clinical cases].
Di Guglielmo R; Vercelli D; Guidi G
Recenti Prog Med; 1979 Apr; 66(4):382-417. PubMed ID: 482726
[No Abstract] [Full Text] [Related]
8. Kinetics of tumor growth and regression in IgG multiple myeloma.
Sullivan PW; Salmon SE
J Clin Invest; 1972 Jul; 51(7):1697-708. PubMed ID: 5040867
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
10. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
[TBL] [Abstract][Full Text] [Related]
11. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
Li J; Wu XB; Zhou Y; Wang X; Chen JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
13. Biclonal gammopathy in multiple myeloma: a case report.
Bakta IM; Sutarka IN
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():544-8. PubMed ID: 10895208
[TBL] [Abstract][Full Text] [Related]
14. Cellular kinetics in multiple myeloma. A new approach to staging and treatment.
Salmon SE; Durie BG
Arch Intern Med; 1975 Jan; 135(1):131-8. PubMed ID: 1089396
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
Rapoport BL; Falkson HC; Falkson G
S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
17. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
[TBL] [Abstract][Full Text] [Related]
18. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
